Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Annovis Bio ( (ANVS) ) is now available.
On April 9, 2026, Annovis Bio priced an underwritten registered direct offering of 5,263,156 shares of common stock, together with accompanying warrants to purchase an equal number of shares, at a combined price of $1.90 per share and warrant. The warrants, exercisable six months after issuance at $2.50 per share and expiring five and a half years later, are expected to bring the company gross proceeds of about $10 million from the stock and warrant sale, with the offering scheduled to close on or about April 10, 2026, subject to customary conditions.
All securities in the deal are being sold by Annovis, with Canaccord Genuity acting as sole bookrunner. The company plans to use the net proceeds primarily to fund the continued Phase 3 clinical development of buntanetap for Alzheimer’s disease, as well as for working capital and general corporate purposes, underscoring its strategy to advance its lead asset in a competitive neurodegenerative disease market.
The most recent analyst rating on (ANVS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Annovis Bio stock, see the ANVS Stock Forecast page.
Spark’s Take on ANVS Stock
According to Spark, TipRanks’ AI Analyst, ANVS is a Neutral.
The score is primarily held down by weak financial performance (no revenue, persistent losses, and worsening cash burn) and bearish technicals (price below major moving averages with negative MACD). A positive Phase 3 safety update provides some support, but long timelines to efficacy readouts and a lack of earnings-based valuation anchor keep the overall score low.
To see Spark’s full report on ANVS stock, click here.
More about Annovis Bio
Annovis Bio, Inc. is a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pa., focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Its lead investigational product, buntanetap, is an oral therapy that targets multiple neurotoxic proteins via an RNA-based mechanism to potentially halt disease progression and improve cognitive and motor function.
Average Trading Volume: 568,342
Technical Sentiment Signal: Strong Sell
Current Market Cap: $45.94M
For a thorough assessment of ANVS stock, go to TipRanks’ Stock Analysis page.